Literature DB >> 22411577

Impact of antihypertensive drugs on TNF-like weak inducer of apoptosis.

Xiaoqi Shen.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22411577     DOI： 10.1007/s10067-012-1969-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  11 in total

1.  Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells.

Authors:  Jerome Galon; Denis Franchimont; Naoki Hiroi; Gregory Frey; Antje Boettner; Monika Ehrhart-Bornstein; John J O'Shea; George P Chrousos; Stefan R Bornstein
Journal:  FASEB J       Date:  2002-01       Impact factor: 5.191

2.  The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells.

Authors:  Mariana J Kaplan; Emily E Lewis; Eric A Shelden; Emily Somers; Robert Pavlic; William J McCune; Bruce C Richardson
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

3.  Lower plasma soluble TWEAK concentration in patients with newly diagnosed hypertension.

Authors:  Nuri Karadurmus; Serkan Tapan; Mustafa Cakar; Ilkin Naharci; Turgay Celik; Ilker Tasci; Selim Sayin; Tolga Dogan; Turker Turker; M Kemal Erbil; Kenan Saglam
Journal:  Clin Invest Med       Date:  2012-02-01       Impact factor: 0.825

4.  Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) mediates p38 mitogen-activated protein kinase activation and signal transduction in peripheral blood mononuclear cells from patients with lupus nephritis.

Authors:  Liu Zhi-Chun; Zhou Qiao-Ling; Liu Zhi-Qin; Li Xiao-Zhao; Zuo Xiao-xia; Tang Rong
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

Review 5.  Molecular mechanisms of anti-inflammatory action of glucocorticoids.

Authors:  A C Cato; E Wade
Journal:  Bioessays       Date:  1996-05       Impact factor: 4.345

6.  Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation.

Authors:  Mahmut Ilker Yilmaz; Juan Jesús Carrero; Jose Luis Martín-Ventura; Alper Sonmez; Mutlu Saglam; Turgay Celik; Halil Yaman; Mujdat Yenicesu; Tayfun Eyileten; Juan Antonio Moreno; Jesús Egido; Luis Miguel Blanco-Colio
Journal:  Clin J Am Soc Nephrol       Date:  2010-04-29       Impact factor: 8.237

7.  Expression of human tumor necrosis factor-like weak inducer of apoptosis in patients with systemic lupus erythematosus.

Authors:  Chao Wang; Li-Li Chen; Hai-Feng Pan; Rui-Xue Leng; Wei-Zi Qin; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2011-10-04       Impact factor: 2.980

8.  TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus.

Authors:  Zeguo Zhao; Linda C Burkly; Sean Campbell; Noa Schwartz; Alberto Molano; Arpita Choudhury; Robert A Eisenberg; Jennifer S Michaelson; Chaim Putterman
Journal:  J Immunol       Date:  2007-12-01       Impact factor: 5.422

Review 9.  The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting.

Authors:  Jeffrey A Winkles
Journal:  Nat Rev Drug Discov       Date:  2008-05       Impact factor: 84.694

10.  Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study.

Authors:  Noa Schwartz; Tamar Rubinstein; Linda C Burkly; Christopher E Collins; Irene Blanco; Lihe Su; Bernard Hojaili; Meggan Mackay; Cynthia Aranow; William Stohl; Brad H Rovin; Jennifer S Michaelson; Chaim Putterman
Journal:  Arthritis Res Ther       Date:  2009-09-28       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.